The US contrast media injectors market is expected to reach US$ 350.4 Mn in 2027 from US$ 183.8 Mn in 2018. The market is estimated to grow with a CAGR of 7.5% from 2019-2027.
The growth of the market is driven by the factors such as increasing number of approvals for contrast agents and increasing number of patients suffering with chronic diseases. However, the market is likely to get affected due to side effects associated with the contrast media agents during the forecast period.
In an aging society where chronic diseases is a leading factor in the health system, technical advancements are necessary to preserve the quality of life through keeping the affordable prices. Chronic diseases can be defined as medical conditions that lasts for one year or more and requires ongoing medical attention or limit activities of daily living. Chronic diseases such as cancer, heart diseases, musculoskeletal diseases, and others are the leading causes of death and disability that requires several imaging modalities for diagnostic and treatment monitoring purposes. According to the National Center for Chronic Disease Prevention and Health Promotion, chronic diseases takes up US$3.3 trillion in annual health care costs.
Additionally, there presence of robust products in the pipeline have been witnessed in the contrast media injectors market. For instance, Lantheus Medical Imaging, Inc., a US based medical imaging company actively involved in the commercialization of contrast media injectors and agents is undergoing clinical trials to develop Flurpiridaz F 18, a novel PET agent, with the first of two Phase 3 trials complete. Moreover, the company has also collaborated with academic centers in the U.S., Canada and the Europe to investigate fluorine-18-based positron emission tomography (PET) radiopharmaceutical imaging agent designed for molecular imaging of the norepinephrine pathway.
The US contrast media injectors market is segmented based on product and application. Among the product segment, the consumables segment is expected to grow at a significant rate of 7.7% during the forecast period. In addition, the segment is also anticipated to dominate the market by products during the year 2027, with a market share of around 65.0%
| Report Attribute | Details |
|---|---|
| Market size in 2018 | US$ 183.8 Million |
| Market Size by 2027 | US$ 350.4 Million |
| CAGR (2019 - 2027) | 7.5% |
| Historical Data | 2016-2017 |
| Forecast period | 2019-2027 |
| Segments Covered |
By Product
|
| Regions and Countries Covered |
United States
|
| Market leaders and key company profiles |
|
The US Contrast Media Injectors Market is valued at US$ 183.8 Million in 2018, it is projected to reach US$ 350.4 Million by 2027.
As per our report US Contrast Media Injectors Market, the market size is valued at US$ 183.8 Million in 2018, projecting it to reach US$ 350.4 Million by 2027. This translates to a CAGR of approximately 7.5% during the forecast period.
The US Contrast Media Injectors Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the US Contrast Media Injectors Market report:
The US Contrast Media Injectors Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The US Contrast Media Injectors Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the US Contrast Media Injectors Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)